H

Healius Ltd
ASX:HLS

Watchlist Manager
Healius Ltd
ASX:HLS
Watchlist
Price: 0.965 AUD -1.03% Market Closed
Market Cap: 700.7m AUD
Section:
 

Relative Value

The Relative Value of one HLS stock under the Base Case scenario is 5.294 AUD. Compared to the current market price of 0.965 AUD, Healius Ltd is Undervalued by 82%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLS Relative Value
Base Case
5.294 AUD
Undervaluation 82%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

0.5
P/S
P/S
Price to Sales
0.5
vs History
87
vs Industry
74
Median 3Y
0.8
Median 5Y
1
Industry
2.3
Forward
0.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
18
Median 3Y
-2
Median 5Y
-1.6
Industry
22.4
Forward
49.4
More Details
2.5
P/OCF
P/OCF
Price to OCF
2.5
vs History
88
vs Industry
53
Median 3Y
3.4
Median 5Y
4
Industry
14.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
34
Median 3Y
-1.7
Median 5Y
-1.7
Industry
21.5
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
30
vs Industry
64
Median 3Y
1
Median 5Y
1.1
Industry
2.2
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
90
vs Industry
59
Median 3Y
1.7
Median 5Y
1.8
Industry
2.5
Forward
1
More Details
1.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.2
vs History
90
vs Industry
74
Median 3Y
2
Median 5Y
2.1
Industry
5.1
More Details
6 870.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6 870.1
vs History
1
vs Industry
5
Median 3Y
29.4
Median 5Y
22.4
Industry
12
Forward
4.9
More Details
6 870.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6 870.1
vs History
1
vs Industry
7
Median 3Y
29.4
Median 5Y
22.4
Industry
17.1
Forward
28
More Details
4.8
EV/OCF
EV/OCF
Enterprise Value to OCF
4.8
vs History
90
vs Industry
46
Median 3Y
7.7
Median 5Y
7.1
Industry
14.7
More Details
6.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
6.3
vs History
88
vs Industry
38
Median 3Y
10.1
Median 5Y
8.2
Industry
18.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
57
vs Industry
66
Median 3Y
0.8
Median 5Y
0.9
Industry
1.8
More Details

Multiples Across Competitors

HLS Competitors Multiples
Healius Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Healius Ltd
ASX:HLS
700.7m AUD 0.5 -4.6 6 870.1 6 870.1
US
CVS Health Corp
NYSE:CVS
98.2B USD 0.2 209.4 13.8 13.8
US
Cigna Corp
NYSE:CI
73.6B USD 0.3 12 7.7 9.8
US
Cigna Group
XMUN:CGN
62.6B EUR 0.3 12 7.7 9.8
DE
Fresenius SE & Co KGaA
XETRA:FRE
27B EUR 1.2 23.6 10.3 15.7
DE
Fresenius Medical Care AG
XMUN:FME
23.6B EUR 1.2 32.9 10.4 22.1
US
Laboratory Corporation of America Holdings
NYSE:LH
21.4B USD 1.6 25 13.6 19
US
Quest Diagnostics Inc
NYSE:DGX
19.8B USD 1.8 20.6 11.4 15.4
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.6B EUR 0.6 16.2 6.4 13.6
US
Guardant Health Inc
NASDAQ:GH
12.5B USD 13.9 -31.3 -33.1 -30.1
US
DaVita Inc
NYSE:DVA
8.5B USD 0.6 11 6.8 9.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
H
Healius Ltd
ASX:HLS
Average EV/EBITDA: 695.8
6 870.1
1 086%
6.3
US
CVS Health Corp
NYSE:CVS
13.8
25%
0.6
US
Cigna Corp
NYSE:CI
7.7
4%
1.9
US
C
Cigna Group
XMUN:CGN
7.7
4%
1.9
DE
Fresenius SE & Co KGaA
XETRA:FRE
10.3
14%
0.7
DE
Fresenius Medical Care AG
XMUN:FME
10.4
10%
1
US
Laboratory Corporation of America Holdings
NYSE:LH
13.6
16%
0.8
US
Quest Diagnostics Inc
NYSE:DGX
11.4
8%
1.4
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
6.4
10%
0.6
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -33.1 N/A N/A
US
DaVita Inc
NYSE:DVA
6.8
4%
1.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
H
Healius Ltd
ASX:HLS
Average EV/EBIT: 699.9
6 870.1
660%
10.4
US
CVS Health Corp
NYSE:CVS
13.8
18%
0.8
US
Cigna Corp
NYSE:CI
9.8
4%
2.4
US
C
Cigna Group
XMUN:CGN
9.8
4%
2.4
DE
Fresenius SE & Co KGaA
XETRA:FRE
15.7
20%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
22.1
25%
0.9
US
Laboratory Corporation of America Holdings
NYSE:LH
19
27%
0.7
US
Quest Diagnostics Inc
NYSE:DGX
15.4
11%
1.4
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.6
25%
0.5
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -30.1 N/A N/A
US
DaVita Inc
NYSE:DVA
9.3
4%
2.3

See Also

Summary
HLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
HLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HLS stock valuation using valuation multiples.
Wall Street Estimates
HLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.